Northern Trust
SPRY icon

Northern Trust’s ARS Pharmaceuticals SPRY Stock Holding History

Northern Trust’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.4M Buy
549,064
+19,780
+4% +$170K ﹤0.01% 2689
2026
Q1 		$4.25M Buy
529,284
+8,275
+2% +$79.3K ﹤0.01% 2545
2025
Q4 		$6.07M Sell
521,009
-10,494
-2% -$102K ﹤0.01% 2360
2025
Q3 		$5.34M Buy
531,503
+46,489
+10% +$667K ﹤0.01% 2459
2025
Q2 		$8.46M Sell
485,014
-2,029
-0.4% -$29.3K ﹤0.01% 2167
2025
Q1 		$6.13M Buy
487,043
+8,890
+2% +$107K ﹤0.01% 2314
2024
Q4 		$5.04M Buy
478,153
+25,773
+6% +$361K ﹤0.01% 2500
2024
Q3 		$6.56M Buy
452,380
+184,809
+69% +$2.2M ﹤0.01% 2320
2024
Q2 		$2.28M Buy
267,571
+5,462
+2% +$48.5K ﹤0.01% 2831
2024
Q1 		$2.68M Buy
262,109
+2,428
+0.9% +$18.1K ﹤0.01% 2814
2023
Q4 		$1.42M Sell
259,681
-1,459
-0.6% -$6.39K ﹤0.01% 3160
2023
Q3 		$987K Buy
261,140
+30,449
+13% +$200K ﹤0.01% 3303
2023
Q2 		$1.55M Buy
230,691
+158,721
+221% +$1.06M ﹤0.01% 3164
2023
Q1 		$469K Buy
71,970
+4,667
+7% +$35.9K ﹤0.01% 3496
2022
Q4 		$574K Buy
67,303
+28,019
+71% +$182K ﹤0.01% 3452
2022
Q3 		$207K Buy
39,284
+2,024
+5% +$9.97K ﹤0.01% 3860
2022
Q2 		$158K Sell
37,260
-136,309
-79% -$475K ﹤0.01% 4009
2022
Q1 		$609K Sell
173,569
-6,289
-3% -$27.4K ﹤0.01% 3665
2021
Q4 		$1.2M Sell
179,858
-5,889
-3% -$47.9K ﹤0.01% 3473
2021
Q3 		$1.85M Buy
185,747
+59,849
+48% +$1.48M ﹤0.01% 3330
2021
Q2 		$3.89M Sell
125,898
-8,686
-6% -$278K ﹤0.01% 2990
2021
Q1 		$5.87M Buy
+134,584
New +$6.37M ﹤0.01% 2656

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Northern Trust's SPRY Position: Q2 2026 in Review

Northern Trust increased its ARS Pharmaceuticals (SPRY) stake by 3.7% in Q2 2026, buying an estimated $170K and bringing the position to 549,064 shares worth $4.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2689.

Northern Trust first reported a position in SPRY in Q1 2021 and has held it in 22 quarters since. The position peaked at $8.46M in Q2 2025. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Northern Trust held 549,064 shares of ARS Pharmaceuticals worth $4.4M as of Q2 2026.
  • Northern Trust bought 19,780 ARS Pharmaceuticals shares in Q2 2026, an estimated $170K.
  • ARS Pharmaceuticals made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #2689 holding.
  • Northern Trust first reported a position in ARS Pharmaceuticals in Q1 2021 and has held it in 22 quarters since.
  • Northern Trust's ARS Pharmaceuticals position peaked at $8.46M in Q2 2025.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.